Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDA FORMAT GUIDELINES: EXCLUDING SUBMISSION OF NON-NDA STUDIES

Executive Summary

NDA FORMAT GUIDELINES: EXCLUDING SUBMISSION OF NON-NDA STUDIES would eliminate the possibility of public disclosure of confidential information, PMA contended in recent comments on FDA's draft guideline for the organization and content of the NDA clinical data section. The assn. told the agency: "It must be pointed out that further development plans for any drug are confidential proprietary information and are not appropriate for inclusion in an application." The FDA draft of the NDA format guideline states that the clinical data section "should include a discussion of any planned evaluation of additional potential indications, such as those approved for related drugs but not yet evaluated for the drug that is the subject of the application." In addition, the draft guideline requires that the filing company report "uses of the new drug or related drug that are fairly widespread but not approved for any agent." PMA pointed out the potential competitive damage that could occur if an NDA sponsor's plans for the drug are disclosed. "If such information were included in the summary basis for approval or otherwise became relasable under freedom of information, the significant economic impact to and the competitive disadvantage for, the applicant is self-evident."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS010307

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel